The big drugmaker's bottom line won't be helped, but millions of people across the world will.
News & Analysis: Pfizer
It's way too early to worry.
There's a pretty good case to be made that it is.
We may see the impact a year from now.
Looking for some extra income in this market? Consider these two blue-chip stocks.
It has to do with getting a step ahead of the coronavirus.
The market size could even be bigger. But the drugmakers still have some hurdles to jump.
If it's steadiness you're after, these two healthcare giants have shown they can perform during a pandemic and beyond.
The need for incentives for vaccination now could point to lower vaccination rates going forward.
A little up-front money can quickly begin making you money with these stocks.